The Protective Roles of Urinary Trypsin Inhibitor in Brain Injury Following Fat Embolism Syndrome in a Rat Model

Lili Xiong1, Linlin Sun2,3, Shanshan Liu2,3, Xingyun Zhu2,3, Ze Teng3, and Junhao Yan2,3

Abstract
Fat embolism syndrome (FES) is a common complication following long bone fracture; fat droplets are released into the blood circulation and form embolisms, mainly in lung and brain. However, the potential mechanisms involved remain to be clarified. In this study, the mechanism of brain injury following FES and the protective effects of urinary trypsin inhibitor (UTI)—a serine protease inhibitor—were investigated. Sixty male Sprague-Dawley rats were divided randomly into sham, FES and FES + UTI treatment groups. The FES model was established using tail vein injection of glycerol trioleate, and UTI was administered by intraperitoneal injection immediately following FES. Brain/lung water content evaluation, Evans blue content and magnetic resonance imaging examination were used to assess the effects of UTI. Furthermore, immunohistochemistry and western blot were also applied to explore the protective mechanism of UTI following FES. The results of oil red O staining indicated that the FES model was successfully established. UTI could significantly attenuate blood-brain-barrier (BBB) disruption, as seen through brain edema evaluation and Evans blue content examination. Immunofluorescence staining results indicated that the TLR4-JNK pathway was involved in brain injury after FES; this effect could be quenched by UTI treatment. Furthermore, UTI could decrease the levels of downstream target proteins of the TLR4-JNK pathway, phosphorylated-NF-kB (p65) and p53 in brain. Our results showed that UTI could alleviate BBB injury after FES through blocking activity of the TLR4-JNK pathway.

Keywords
fat embolism syndrome, urinary trypsin inhibitor, inflammation, apoptosis, rat

Introduction
Fat embolism syndrome (FES) is an embolic disease. Circulating fat can be embolized in several organs, notably in lungs and brain1,2, and FES is a potentially life-threatening disease3. FES can occur following long-bone fractures and fat crushing2. The main symptoms of FES include pulmonary injury (tachypnea and dyspnea) and neurological deficits (confusion, drowsiness, or coma), and dermatological lesions (petechial rash)4.

So far, most studies on FES have focused on lung injury because it is believed that fat droplets in the blood occlude mainly lung capillaries5. However, neurological signs, which can precede the development of respiratory symptoms and may be the primary signs6, are reported in up to 86% of FES patients7. Although death induced by FES is commonly attributed to pulmonary insufficiency8, some patients who die have usually been deeply comatose. The role of brain injury following FES has been considered as a primary cause of death9. Although damage to the blood-brain-barrier (BBB, formed by endothelial cells, basement membrane, astrocytes and pericytes) is involved in pathology of FES10, the specific mechanisms involved still need further investigation.

The mechanism of injury following FES involves a mechanical embolic phase followed by a biochemical response. The mechanical phase includes the blockage of...
capillaries, such as in lungs and brain, which results in venoarterial shunting and hypoxemia. The biochemical phase begins with free fatty acids (FFAs) produced by the fat. FFAs in the lung parenchyma lead to disruption of alveolar capillary membranes, interstitial hemorrhage, and pulmonary edema. However, the damage that FES causes to brain, and its mechanism, has not yet been fully elucidated. Using magnetic resonance imaging (MRI) examination, morphological, and western blot methods, the present study explores capillary injury in brain after FES.

Toll-like receptor 4 (TLR4) is a member of the TLR family, which recognize distinct microbial components and mediate innate immune responses for host defense. Inappropriate activation of TLR4 and its downstream mitogen-activated protein kinase (MAPK) pathways, e.g., c-jun N-terminal kinase (JNK) will initiate inflammation and apoptosis cascades and lead to severe inflammatory and autoimmune injuries.

Urinary trypsin inhibitor (UTI) is a Kunitz-type protease inhibitors found in human urine and synthesized from inter-α-trypsin inhibitor. UTI has been used for treatment of acute pancreatitis and circulatory shock. UTI can inhibit plasmin, chymotrypsin, and neutrophil elastase as well as trypsin. It can suppress the production of TNF-α from lipopolysaccharide (LPS)-activated macrophages. It is also reported that UTI can protect the BBB integrity through blocking the inflammatory and apoptotic pathway after subarachnoid hemorrhage. Whether UTI can also protect brain tissue from FES injury, and the mechanism of such protection, still need further study.

In this study, the roles of UTI in maintaining BBB integrity after FES were explored, and the potential mechanisms were also investigated. The results indicated that UTI could protect the BBB through blocking inflammatory and apoptotic cascades in capillaries following FES.

Materials and Methods

All procedures were performed following protocols approved by the Association of Medical Ethics of Peking University Health Science Center in Beijing, China.

Establishment of FES Model

The whole study design is shown in Fig 1. Male Sprague-Dawley rats (280–300 g) were purchased from Peking University Health Science Center. The animals were allowed free access to food and water, and housed in a 12-h dark/light cycle in a temperature- and humidity-controlled environment.

The animals were divided randomly into three groups: (1) Sham group (n = 20); (2) FES+NS (normal saline) group (n = 20); (3) FES + UTI group (n = 20).

The rats were anaesthetized by intraperitoneal administration of pentobarbital sodium (50 mg/kg; Abbott Laboratory, North Chicago, IL, USA). The FES model was established by intravenous injection of 0.2 ml triolein (1,2,3-tri[cis-9-octadecenoyl]glycerol, CAS: 122-32-7, Sigma, St. Louis, MO, USA) into the caudal vein. In sham group, the rats were intravenously administered 0.2 ml NS. In the FES + UTI group, UTI (50,000 U/kg, Techpool Biopharma Co., Ltd, China) was administered intravenously 30 min after administration of triolein, as reported previously.

Water Content Measurement

The animal’s brain and lungs were harvested at 12 h following FES. The brain was divided into left hemisphere, right hemisphere, cerebellum and brainstem, as previously described. The specimens were weighed immediately (wet weight) and weighed again after drying in an oven at 105°C for 72 h (dry weight). The water content was calculated using the following formula: (wet weight − dry weight)/wet weight × 100%.

Magnetic Resonance Imaging

MRI (T2 weighted image, T2WI) was performed as reported by others. In this study, the hippocampus is the region of interest (ROI) due to its higher sensitivity to hypoxia or edema than other brain regions following FES.
At 12 h following FES, the anesthetized rat was placed on a special frame in supine position, and introduced into a 3.0-Tesla MRI animal scanner (Siemens, Munich, Germany). The head of the rat was set in a “birdcage coil” (diameter = 30 mm). A T1-weighted image sequence was conducted for orientation of subsequent scans. A muscle relaxant was applied continuously via the femoral artery to minimize movement artifacts (diluted atracurium besilate, initial bolus 4 mg/kg followed by 4.5 mg/h; Glaxo Wellcome, Brentford, UK).

T2WI was performed using the following parameters: repetition time (TR) = 2500 ms; echo time (TE) = 8.1–65.6 ms; flip angle = 90°; matrix = 0.63 mm × 0.63 mm; slice thickness = 2 mm; number of averages = 1; echo train length = 1. The data sets of T2WI consisted of eight consecutive, 2-mm thick slices without slice gap. All process was conducted by two experienced, independent radiologists. The T2 values of hippocampus each group were recorded and analyzed.

**Immunohistochemical Staining**

Immunohistochemical staining was performed as reported previously by others. The brains or lungs were fixed by cardiovascular perfusion with 0.01 mol/L PBS and 4% paraformaldehyde (PFA), and then postfixed in 4% paraformaldehyde (PFA) and incubated with primary antibody overnight at 4°C. The primary antibodies (1:1000) were mouse anti-cleaved caspase-3 (Santa Cruz Biotechnology), rabbit anti-activated NF-κB (p65), rabbit anti-phosphorylated p53 (Cell Signaling Technology), and mouse anti-TNF-α, rabbit anti-activated caspase-3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The sections were then treated with the corresponding species ABC Kit (Santa Cruz Biotechnology). Peroxidase activity was detected using 3-diaminobenzidine (DAB) and H2O2 for 5 min. The sections were dehydrated and coverslipped.

The sections for immunofluorescence staining were incubated overnight with primary antibodies for TLR4 and phosphorylated JNK (Cell Signaling Technology). The sections were treated with the corresponding fluorescence labeled second antibodies (1:200, Santa Cruz Biotechnology). The results were observed with the microscope (Olympus BX51, Tokyo, Japan). Serum was applied instead of primary antibody as the negative control.

**Oil Red O Staining**

Frozen tissue sections (10 μm thickness) were stained for 5 min with a filtered solution of 1% oil red O in 60% aqueous triethylphosphate and then mounted in glycerin jelly, as reported previously.

**TUNEL Staining**

The apoptosis of endothelial cells was observed using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) method. Brain tissue sections were stained using a TUNEL Kit (Roche, New York, NY, USA), and TUNEL-positive cells were revealed by fluorescein-dUTP with dNTP and POD with DAB as described previously.

**Western Blot**

Western blotting was performed as reported by others. Rats under deep anesthesia were perfused transcardially with 250 mL 0.1 mol/L PBS (pH 7.4). The bilateral hippocampi were harvested and homogenized in RIPA lysis buffer (Santa Cruz Biotechnology) followed by centrifugation at 14,000 g at 4°C for 30 min. The protein concentration of the supernatant was measured using a detergent compatible assay (Bio-Rad, Hercules, CA, USA). The protein sample (40 μg) was loaded on a Tris glycin gel, electrophoresed, and transferred on a nitrocellulose membrane, and then blocked with blocking solution and incubated with primary antibody overnight at 4°C. The primary antibodies (1:1000) were mouse anti-phosphorylated NF-κB (p65), rabbit antiphosphorylated p53 (Cell Signaling Technology), and mouse anti-TNF-α, rabbit anti-cleaved caspase-3 (Santa Cruz Biotechnology). Nitrocellulose membranes were then incubated with the corresponding secondary antibodies (1:2000, Santa Cruz Biotechnology) for 1 h. The bands were probed with a chemiluminescence reagent kit (Amersham Bioscience, Arlington Heights, IL, USA) and quantified by densitometry with Image J software (National Institutes of Health, Bethesda, MD, USA). β-Actin was also blotted on the same membrane as the loading control.

**Statistical Analysis**

All data were expressed as mean ± standard deviation (SD), and were analyzed by one-way analysis of variance (ANOVA) with the Tukey-Kramer post hoc tests using Systat software (version 4.0, Systat, San Jose, CA, USA). A P-value of less than 0.05 was considered statistically significant.

**Results**

**Establishment of FES Model**

First, we evaluated the validity of the FES model in this study. The results of oil red O staining showed that there are numerous fat droplets distributed in the capillaries of both lungs and brain. These indicated that fat droplets from caudal veins embolized successfully in the brain capillaries, and played their mechanical and biochemical roles. Additionally, we used Evans blue as an albumin...
indicator in blood to assess BBB permeability. Normally, Evans blue cannot infiltrate into the brain parenchyma owing to BBB resistance. However, in the FES model, the Evans blue content in the hippocampus increased markedly, which revealed BBB injury in the brain following FES (Fig 2C). Furthermore, MRI (T2WI) results also showed that the UTI could alleviate edema in bilateral hippocampi (Fig 3C). These results indicated that UTI played an important protective role in maintaining BBB integrity following FES; however, the specific mechanism still needed further investigation.

**The Protective Effects of UTI**

After UTI treatment, the Evans blue content in the hippocampus decreased markedly (Fig 2C). In addition, the water content in brain and lungs also declined significantly following UTI treatment (Fig 3A, B). Furthermore, MRI (T2WI) results also showed that the UTI could alleviate edema in bilateral hippocampi (Fig 3C). These results indicated that UTI played an important protective role in maintaining BBB integrity following FES; however, the specific mechanism still needed further investigation.

**Mechanism of UTI Effects**

Since fat droplets were distributed in the lumens of brain capillaries, we observed pathological lesions of endothelial cells following FES. The immunofluorescence staining results revealed that TLR4 and p-JNK were both activated in endothelial cells following FES, and UTI treatment could significantly quench their activities (Fig 4). The immunohistochemistry staining results showed that downstream pathway proteins, such as NF-κB (p65), TNF-α, p53, and cleaved caspase-3, in endothelial cells were increased after FES, an effect that could be attenuated by UTI treatment (Fig 5). Additionally, TUNEL staining results showed that UTI treatment could alleviate endothelial cell loss through blocking the apoptosis cascade following FES (Fig 5). Furthermore, western blot results showed that expression levels of NF-κB (p65), TNF-α, p-p53, and cleaved caspase-3 in hippocampi were also enhanced, which could be downregulated by UTI administration (Fig 6).

**Discussion**

In this study, we explored the potential mechanism of brain injury following FES, and the effects of UTI in alleviating injury. The results indicated that, after FES, there was BBB disruption due to the loss of endothelial cells induced by inflammation and apoptosis cascades. UTI, as an α-trypsin inhibitor, played protective roles in maintaining BBB integrity through its anti-inflammatory and anti-apoptosis effects.

FES is a clinically significant problem, particularly after bone fractures and joint replacements. Respiratory dysfunction, neurological symptoms, and a petechial rash are the major diagnostic features for FES. Neurological signs have been reported in up to 86% of patients, and may be the primary cause of death.

There are two opinions as to the cause of FES. One theory maintains that the intramedullary fat is absorbed into the circulation as emboli after a fracture. The other believes that FFAs are released when lipase produced by the lungs acts on embolic fats. FFAs are toxic to pulmonary or brain endothelial cells, and can lead to interstitial and alveolar hemorrhage, edema, and even acute respiratory distress syndrome (ARDS).
There are two types of injury following FES: a mechanical embolic phase, and a biochemical or metabolic response. The mechanical phase involves blockage of capillaries, resulting in hypoxemia, and hypoperfusion in the lungs or brain. The biochemical damage begins after the capillaries filter fat droplets. Lipoprotein lipase, secreted by endothelial cells in the capillary walls, the fat and triglycerides into FFAs, which are toxic to the endothelial cells of organs.

There are three methods to establish the FES model, one is tail vein injection of triolein; the second is to take body fat and inject it into the femoral vein; finally, there is a method of artificial fractures to establish the model. In this study, we used the method of triolein injection from the caudal vein, using oil O staining (a specific method to detect fat). The fat emboli were found distributed in lungs and brain, which indicated that the rat FES model used in this study could accurately simulate the clinical FES situation; therefore, reliable data about the injury mechanisms of FES and the effects of UTI could be obtained in this study.

So far, greater attention has been paid to lung damage after FES; however, brain injury is a common symptom following FES. Although it is reported that BBB injury occurs after FES, the mechanism of pathogenesis is not fully understood. In this study, we measured the water content and Evans blue content in the brain. The brain water content was significantly increased after FES; furthermore, the Evans blue content in the hippocampus also increased markedly. These results showed that there is definite vasogenic edema in brain tissue induced by BBB disruption after FES.

Additionally, MRI T2WI was also applied to explore edema after FES, since this method can sensitively detect the vasogenic edema resulting from BBB disruption. The T2 signal intensity increased markedly following FES, which indicated that vasogenic edema induced by BBB injury occurred in brain tissue.

Since there was some evidence of BBB disruption after FES, we next explored the pathological mechanism of BBB disruption.
damage. The BBB is composed of blood vessels whose endothelial cells display specialized tight junctions and extremely low rates of transcellular vesicular transport (transcytosis). The BBB can block some macromolecules from entering the brain, and it controls substance influx and efflux. In this study, after FES, TUNEL staining showed that apoptotic endothelial cells were increased markedly, which could result in BBB disruption and dysfunction, e.g., edema.

To clarify the mechanism of endothelial cell apoptosis, we performed immunohistochemical staining of hippocampus capillaries. The immunofluorescence staining results revealed that the TLR4-JNK pathway was activated following FES. The evolutionarily conserved TLR family can recognize distinct microbial components and mediate innate immune responses for host defense. TLR4 are expressed constitutively in bone-marrow-derived cells and in a number of mucosal cells. A number of studies have demonstrated that TLR4 plays a key role in the mucosal inflammation caused by ischemia/reperfusion (I/R) in hepatic I/R, intestinal I/R, cardiac I/R, and hemorrhagic shock. Activation of TLR4 can stimulate MAPK pathways, e.g., JNK, which lead to activation of NF-κB and p53 pathway, and initiate the inflammation and apoptosis pathologies.

The immunohistochemical staining indicated that NF-κB (p-p65), p-p53, TNF-α, and cleaved caspase-3 in endothelial cells were enhanced, which indicated that the inflammation and apoptosis cascades were activated within the capillaries following FES. Additionally, the western blot results also confirmed these findings. Therefore, there was obvious BBB disruption in the brain after FES, which might be an important mechanism responsible for brain injury.

UTI is a protease inhibitor purified from human urine. UTI can inhibit the activities of proteases such as trypsin,
chymotrypsin, and elastase. It can also stabilize lysosomal membrane, and suppress the release of lysosomal enzymes. Additionally, UTI can reduce the production of cytokine-induced neutrophil chemoattractants and decrease neutrophil accumulation, and thereby alleviate neutrophil-induced endothelial injury. UTI can block the activation of inflammation and apoptosis pathways. It is reported that UTI can attenuate reperfusion injury in the ischemic intestine, liver, and kidney. Furthermore, it can decrease TNF-α production in the rat I/R liver. It is also reported that UTI can inhibit the apoptosis of endothelial cells. However, the effects of UTI on maintaining BBB integrity following FES has not yet been studied. In this study, UTI significantly reduced brain water content and Evans blue content after FES, and T2WI results also showed UTI can alleviate brain edema. These results indicated that UTI treatment could attenuate BBB injury following FES.

After observing the protective roles of UTI on BBB, we next explored the potential mechanism of UTI’s effects. The results of immunofluorescence staining showed that UTI could quench the activity of the TLR4-JNK pathway in endothelial cells. Additionally, after UTI treatment, the expression level of downstream targets in the TLR4-JNK pathway, such as inflammatory factor NF-κB(p-p65), TNF-α, apoptotic factor p-p53, and cleaved caspase-3, were significantly decreased. More importantly, TUNEL-positive-staining endothelial cells were decreased, too. These results implied that the protective effects of UTI on BBB integrity might be through attenuating inflammation and apoptosis via blocking activities of the TLR4-JNK pathway and its downstream targets.

**Conclusion**

In this study, we found that BBB disruption might be one of primary brain injuries following FES due to fat emboli in capillaries. UTI could play its protective roles in maintaining BBB integrity through alleviating apoptosis and inflammation cascades in endothelial cells via suppression of the TLR4-JNK pathway.

**Ethical Approval**

This study was approved by the Association of Medical Ethics of Peking University Health Science Center in Beijing, China.

**Statement of Human and Animal Rights**

This article contains animal studies approved by the Association of Medical Ethics of Peking University Health Science Center in Beijing, China.
Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Techpool Research Fund (No. UF2018332); the interdisciplinary medicine Seed Fund of Peking University(Grant No. BMU2018MC001).

References

1. Mellor A, Soni N. Fat embolism. Anaesthesia. 2001;56(2): 145–154.
2. Bolliger SA, Muehlematter K, Thali MJ, Ampanozi G. Correlation of fat embolism severity and subcutaneous fatty tissue crushing and bone fractures. Int J Legal Med. 2011;125(3): 453–458.
3. de Feiter PW, van Hooft MA, Beets-Tan RG, Brink PR. Fat embolism syndrome: Yes or no? J Trauma. 2007;63(2): 429–431.
4. Parisi DM, Koval K, Egel K. Fat embolism syndrome. Am J Orthop (Belle Mead NJ). 2002;31(9):507–512.
5. Takada M, Chiba S, Nagai T, Takeshita H, Kanno S, Ikawa T, Sakamoto K, Sagi M, Ichiba K, Mukai T. Inflammatory responses to neutral fat and fatty acids in multiple organs in a rat model of fat embolism syndrome. Forensic Sci Int. 2015; 254:126–132.
6. Caricato A, Russo G, Biasucci DG, Annetta MG. Fat embolism syndrome. Intensive Care Med. 2017;43(9):1411–1412.
7. Talbot M, Schemitsch EH. Fat embolism syndrome: history, definition, epidemiology. Injury. 2006;37(Suppl 4):S3–S7.
8. Volpin G, Gorski A, Shtraker H, Makhoul N. Fat embolism syndrome following injuries and limb fractures. Harefuah. 2010;149(5):304–308.
9. Voisard MX, Schweitzer W, Jackowski C. Pulmonary fat embolism—a prospective study within the forensic autopsy collective of the Republic of Iceland. J Forensic Sci. 2013; 58(Suppl 1):S105–111.
10. Drew PA, Smith E, Thomas PD. Fat distribution and changes in the blood brain barrier in a rat model of cerebral arterial fat embolism. J Neurol Sci. 1998;156(2):138–143.
11. Zhang Y, Tian K, Wang Y, Zhang R, Shang J, Jiang W, Wang A. The effects of aquaporin-1 in pulmonary edema induced by fat embolism syndrome. Int J Mol Sci. 2016;17(7). pii: E1183.
12. Wang HD, Zheng JH, Deng CL, Liu QY, Yang SL. Fat embolism syndromes following liposuction. Aesthetic Plastic Surg. 2008;32(5):731–736.
13. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
14. Barton GM, edzhitov R. Toll-like receptor signaling pathways. Science. 2003;300(5625):1424–1425.
15. Gáspár Pipicz M, Hawchar F, Kovács D, Djinackor L, Görbe A, Varga ZV, Kiricsi M, Petrovszki G, Gácsor A, Csonka C, Csont T. The cytoprotective effect of biglycan core protein involves Toll-like receptor 4 signaling in cardiomyocytes. J Mol Cell Cardiol. 2016;99:138–150.
16. Backhed F, Hornef M. Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? Microbes Infect. 2003;5(11):951–959.
17. Masuda T, Sato K, Noda C, Ikeda KM, Matsunaga A, Ogura MN, Shimizu K, Nagasawa H, Matsuyama N, Izumi T. Protective effect of urinary trypsin inhibitor on myocardial mitochondrial during hemorrhagic shock and reperfusion. Crit Care Med. 2003;31(7):1987–1992.
18. Kikuchi I, Uchimani H, Nanjo H, Hashimoto M, Nakajima A, Kume M, Mencin A, Yamamoto Y. Clinical and prognostic significance of urinary trypsin inhibitor in patients with hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2009;16(10):2805–2817.
19. Onai H, Kudo S. Suppression of superantigen-induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor. Eur J Clin Invest. 2001;31(3):272–280.
20. Chen Q, Hu C, Liu Y, Liu Y, Wang W, Zheng H, Rong L, Jia J, Sun S, Yu C, Liu YM. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study. PLoS One. 2017;12(5): e0177425.
21. Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Fujie M, Nishida T, Takigawa M, Terao T. Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8. J Biol Chem. 2001;276(17):13650–13656.
22. Zhou N, Xu T, Bai Y, Prativa S, Xu JZ, Li K, Han HB, Yan JH. Protective effects of urinary trypsin inhibitor on vascular permeability following subarachnoid hemorrhage in a rat model. CNS Neurosci Ther. 2013;19(9):659–666.
23. Ito K, Mizutani A, Kira S, Mori M, Iwasaka H, Neguchi T. Effect of Ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury. 2005;36(3):387–394.
24. Zhang Y, Sun J, Zhu S, Xu T, Lu J1, Han H, Zhou C, Yan J. The role of rhynchophylline in alleviating early brain injury following subarachnoid hemorrhage in rats. Brain Res. 2016; 1631:92–100.
25. Xu T, Zhang WG, Sun J, Zhang Y, Lu JF, Han HB, Zhou CM, Yan JH. Protective effects of thrombomodulin on microvascular permeability after subarachnoid hemorrhage in mouse model. Neuroscience. 2015;299:18–27.
26. Sharma HS, Patnaik R, Sharma A, Lafuente JV, Miclescu A, Winklun L. Cardiac arrest alters regional ubiquitin levels in association with the blood-brain barrier breakdown and neuronal damages in the porcine brain. Mol Neurobiol. 2015;52(2):1043–1053.
27. Kaza AK, Cope JT, Fiser SM, Long SM, Kern JA, Kron IL, Tribble CG. Elimination of fat microemboli during cardiopulmonary bypass. Ann Thorac Surg. 2003;75(2):555–559.
28. Tourchi A, Shabaninia M, Stewart M, Miyamoto H, Di Carlo H, Gearhart JP. Complete penile disassembly for repair of epispadias causes erectile tissue alteration through transforming growth factor beta 1 overexpression in a rabbit model. Urology. 2018;111:151–156.
29. Hsieh HL, Chi PL, Lin CC, Yang CC, Yang CM. Up-regulation of ROS-dependent matrix metalloproteinase-9 from high-glucose-challenged astrocytes contributes to the neuronal apoptosis. Mol Neurobiol. 2014;50(2):520–533.
30. Eriksson EA, Pellegrini DC, Vanderkolk WE, Minshall CT, Hidaka H, Ishihara K, Uchino S, Furuhashi T, Yamada S, Mori T. Ulinastatin, a protease inhibitor, attenuates intestinal ischemia/reperfusion injury. Transplant Proc. 1994;26(4):2423–2425.
31. McIff TE, Poisner AM, Herndon B, Lankachandra K, Molteni A, Adler F. Mitigating effects of captopril and losartan on lung histopathology in a rat model of fat embolism. J Trauma. 2011;70(5):1186–1191.
32. Blankstein M, Byrick RJ, Richards RR, Mullen JB, Zdero R, Schemitsch EH. Pathophysiology of fat embolism: a rabbit model. J Orthop Trauma. 2011;25(11):674–680.
33. Inoue H, Hanagama M, Kamiya M, Shinone K, Nata M. Experimental pulmonary fat embolism induced by injection of triolein in rats. Leg Med (Tokyo). 2008;10(1):26–30.
34. Yang J, Li Q, Wang Z, Qi C, Han X, Lan X, Wan J, Wang W, Zhao X, Hou Z, Gao C, Carhuapoma JR, Mori S, Zhang J, Wang J. Multimodality MRI assessment of grey and white matter injury and blood-brain barrier disruption after intracerebral haemorrhage in mice. Sci Rep. 2017;7:40358.
35. Benzvi A, Lacoste B, Kur E, Andrecou BJ, Mayshar Y, Yan H, Gu C. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature. 2014;509(7501):507–511.
36. Zhai Y, Shen XD, O’Connell R, Gao F, Lassman C, Busuttil RW, Cheng G, Kupiec-Weglinski JW. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol. 2004;173(12):7115–7119.
37. Moses T, Wagner L, Fleming SD. TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion induced damage. J Leukoc Biol. 2009;86(4):971–980.
38. Oyama J, Blais C Jr, Liu X, Pu M, Kohzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004;109(6):784–789.
39. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA. 1998;95(18):10541–10546.
40. Song Z, Zhao X, Liu M, Jin H, Cui Y, Hou M, Gao Y. Recombinant human brain natriuretic peptide attenuates LPS-induced cellular injury in human fetal lung fibroblasts via inhibiting MAPK and NF-κB pathway activation. Mol Med Rep. 2016;14(2):1785–1790.
41. Shi L, Zhao S, Chen Q, Wu Y, Zhang J, Li N. Crocin inhibits RANKL-induced osteoclastogenesis by regulating JNK and NF-κB signaling pathways. Mol Med Rep. 2018;17(6):7947–7951.
42. Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs. 2010;19(4):513–520.
43. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol. 2001;69(2):241–247.
44. Liu N, Jiang Z, Liu Y, Nie Y, Chen J, Ouyang B, Guan X, Chen M. Human trypsin inhibitor reduces the apoptosis of lipopolysaccharide induced human kidney 2 cells by promoting mitochondrial fusion. Mol Med Rep. 2017;16(3):2899–2906.
45. Wang J, Chen X, Su L, Zhu Z, Wu W, Zhou Y. Suppressive effects on cell proliferation and motility in gastric cancer SGC-7901 cells by introducing ulinastatin in vitro. Anticancer Drugs. 2016;27(7):651–659.
46. Li XK, Suzuki H, Kimura T, Kawabe A, Uno T, Harada Y. Ulinastatin, a protease inhibitor, attenuates intestinal ischemia/reperfusion injury. Transplant Proc. 1994;26(4):2423–2425.
47. Yamaguchi Y, Ohshiro H, Nagao Y, Odawara K, Okabe K, Hidaka H, Ishihara K, Uchino S, Furushashi T, Yamada S, Mori K, Ogawa M. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res. 2000;94(2):107–115.
48. Nakahama H, Obata K, Sugita M. Ulinastatin ameliorates acute ischemic renal injury in rats. Ren Fail. 1996;18(6):893–898.
49. Aihara T, Shiraishi M, Hiroyasu S, Hatsuse K, Mochizuki H, Seki S, Hiraide H, Muto Y. Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Transplant Proc. 1998;30(7):3732–3734.